Similarly, sotorasib was evaluated in an international single-arm phase II trial in patients with locally advanced unresectable or metastatic CRC with a KRAS G12C mutation who had progressed on prior fluoropyrimidine, oxaliplatin, and irinotecan. This evidence concerns the gene KRAS and colorectal carcinoma.